GlassScriptPhysician profile
Jocelyn Campo
NPI 1235853987
$8,825.97
in general payments reported to CMS, 2019-2025
45 companies · $3,954 in 2025
The $3,954 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,852 · 2024: $3,020 · 2025: $3,954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,728 · Education: $98.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,727.82 |
| Education | $98.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,336.10 | 2023-2025 | |
| Amgen INC. | $697.46 | 2023-2025 | Tavneos, Evenity, Enbrel |
| Glaxosmithkline, LLC. | $658.79 | 2023-2025 | Benlysta |
| Ucb, INC. | $625.73 | 2023-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $570.60 | 2024-2025 | Tremfya |
| Lilly USA, LLC | $501.69 | 2023-2025 | Taltz, Zepbound, Olumiant |
| Mallinckrodt Hospital Products INC. | $487.90 | 2023-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $404.79 | 2023-2025 | Saphnelo |
| Otsuka America Pharmaceutical, INC. | $379.82 | 2023 | Rexulti, Abilify Maintena, Nuedexta |
| Genzyme Corporation | $360.93 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $360.54 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $325.54 | 2024-2025 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.28 | 2023-2025 | Cyltezo, Ofev |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $221.34 | 2023 | |
| Pfizer INC. | $171.82 | 2024-2025 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $156.94 | 2024-2025 | |
| Axsome Therapeutics, INC. | $142.54 | 2023 | Auvelity |
| Fresenius Kabi USA, LLC | $117.36 | 2024-2025 | |
| Radius Health, INC. | $102.85 | 2024-2025 | Tymlos |
| Janssen Pharmaceuticals, INC | $95.18 | 2023-2024 | Invega Sustenna, Invega Trinza, Spravato |
| Organon LLC | $89.79 | 2023-2025 | Hadlima |
| Vanda Pharmaceuticals INC. | $80.31 | 2023 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $72.71 | 2023 | Trintellix |
| Scilex Pharmaceuticals INC. | $61.30 | 2024 | |
| Alexion Pharmaceuticals, INC. | $61.24 | 2023-2025 | Strensiq |
| Kiniksa Pharmaceuticals International, Plc | $58.59 | 2024 | Arcalyst |
| Neurocrine Biosciences, INC. | $51.63 | 2023 | Ingrezza |
| Aurinia Pharma U.S., INC. | $48.41 | 2025 | Lupkynis |
| Genentech USA, INC. | $32.81 | 2024-2025 | Actemra |
| Actelion Pharmaceuticals US, INC. | $29.14 | 2025 | Opsumit |
| Idorsia Pharmaceuticals US INC | $26.73 | 2023 | Quviviq |
| Invivyd INC | $26.04 | 2025 | Pemgarda |
| Alkermes, INC. | $25.58 | 2023 | Lybalvi |
| Acadia Pharmaceuticals INC | $24.13 | 2023 | Nuplazid |
| Tonix Medicines, INC. | $21.35 | 2025 | Tonmya |
| Celgene Corporation | $20.63 | 2024 | Orencia |
| Tris Pharma INC | $20.56 | 2023 | Dyanavel Xr |
| Celltrion USA INC. | $18.16 | 2023 | Yuflyma |
| Teva Pharmaceuticals USA, INC. | $17.38 | 2023 | Austedo Xr |
| Sandoz INC. | $16.45 | 2024 | |
| Bausch Health US, LLC | $15.60 | 2023 | Aplenzin |
| Neos Therapeutics, LP | $15.56 | 2023 | Adzenys Xr-Odt |
| Corium, LLC | $15.47 | 2023 | Azstarys |
| Biogen, INC. | $14.39 | 2023 | |
| Lundbeck LLC | $13.81 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jocelyn Campo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.